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Abstract
Background/Aims: The atherosclerotic apolipoprotein E-deficient (apoE-/-) mouse exhibits 
impaired vasodilation and enhanced vasoconstriction responsiveness. The objectives of this 
study were: a) to determine the relative contribution of cyclooxygenases (Cox-1 and Cox-2), 
thromboxane A2 (TXA2) and endothelin-1 (ET-1) to enhancing vascular hyperresponsiveness 
in this model of atherosclerosis and b) to investigate the beneficial effects of the 
phosphodiesterase 5 inhibitor sildenafil on this endothelial dysfunction. Methods: Adult male 
apoE-/- mice were treated with sildenafil (40 mg/kg/day, for 3 weeks) and compared with non-
treated ApoE-/- and wild-type mice. The beneficial effects of sildenafil on vascular contractile 
response to phenylephrine (PE) in aortic rings were evaluated before and after incubation 
with Cox-1 (SC-560) or Cox-2 (NS-398) inhibitors or the TP antagonist SQ-29548, and on 
contractile responsiveness to ET-1. Results: ApoE-/- mice exhibited enhanced vasoconstriction 
to PE (Rmax ~35%, p<0.01), which was prevented by treatment with sildenafil. The enhanced 
PE-induced contractions were abolished by both Cox-1 inhibition and TP antagonist, but were 
not modified by Cox-2 inhibition. Aortic rings from ApoE-/- mice also exhibited enhanced 
contractions to ET-1 (Rmax ~30%, p<0.01), which were attenuated in sildenafil-treated 
ApoE-/- mice. In addition, we observed augmented levels of vascular proinflammatory cytokines 
in ApoE-/- mice, which were partially corrected by treatment with sildenafil (IL-6, IL-10/IL-6 
ratio and MCP-1). Conclusion: The present data show that the Cox-1/TXA2 pathway prevails 
over the Cox-2 isoform in the mediation of vascular hypercontractility observed in apoE-/- 
mice. The results also show a beneficial effect of sildenafil on this endothelial dysfunction and 
on the proinflammatory cytokines in atherosclerotic animals, opening new perspectives for 
the treatment of other endothelium-related cardiovascular abnormalities.
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Introduction
Atherosclerosis (AT) is a complex vascular inflammatory disease of conductance arteries 
and its subclinical condition is an important trigger of future unfavorable cardiovascular 
outcomes, such as cerebrovascular events or acute myocardial infarction [1-4]. It is 
initiated and sustained by a combination of endothelial dysfunction and chronic exposure 
to modifiable risk factors (e.g. inadequate lifestyle) and non-modifiable risk factors (e.g. 
aging and male gender), which have been widely demonstrated by experimental [2, 5-8] and 
clinical studies [9-12].
In the last three decades, genetically modified mice have been extensively used as 
models for understanding the causes and mechanisms involved in human diseases and have 
contributed to the consolidation of translational research in cardiovascular and metabolic 
disorders [5, 7, 8, 13, 14]. Among the available models, the apoE-/- mouse was the first and 
most widely used for this purpose. Loss of apoE gene expression in this animal compromises 
the hepatic clearance of VLDL and LDL, leading to spontaneous hypercholesterolemia [1, 
3, 7]. Moreover, apoE-/- mice exhibit impaired vasodilation and enhanced vasoconstriction 
responsiveness, which are hallmarks of endothelial dysfunction in this experimental model 
and in atherosclerotic humans [4, 5, 7]. Previous studies have contributed to understanding 
of the mechanisms of impaired relaxation of both resistance and conductance vasodilation in 
the apoE-/- mouse [7, 15]. However, the mechanisms underlying vascular hypercontractility, 
and approaches to correct this disturbance in this model, have not yet been completely 
elucidated. Thus, there is a need for research into putative therapies to treat and prevent the 
vascular endothelium-dependent hypercontractility that is commonly observed in chronic 
cardiovascular diseases, including AT.
More recently, our laboratory and others have investigated some mechanisms for 
the progression of AT, and alternative strategies to improve endothelial function using the 
apoE-/- model [5, 7, 15-17]. In this context, we and others have previously shown that the 
decreased endothelium-dependent vasodilation response to acetylcholine observed in this 
atherosclerotic model is mainly due to decreased bioavailability of nitric oxide, increased 
production of reactive oxygen species (ROS) and chronic inflammation [7, 15, 16, 18, 19]. In 
addition, we demonstrated an exacerbated vasoconstrictor response to sympathetic agonists 
in the same experimental model, with relative contribution of eicosanoids and ROS using 
nonselective cyclooxygenase (Cox-1/Cox-2) and NADPH oxidase inhibitors, respectively 
[18, 20]. In parallel, our laboratories [15, 18, 21-23] and others [24, 25] have published 
several data supporting the idea that chronic use of sildenafil, a phosphodiesterase 5 (PDE5) 
inhibitor, improves endothelial function in the apoE-/- mouse. However, the beneficial effects 
of this drug on the prostanoid vasoconstrictors and on inflammatory cytokines have not yet 
been evaluated in this suitable animal model of AT [26, 27].
The present study was therefore designed to determine whether the exaggerated 
contractile response observed in conductance vessels from apoE-/- mice could be mediated 
by: 1) eicosanoids derived from COX-1 or COX-2) pathways, 2) enhanced responsiveness to 
endothelin 1 (ET-1) and 3) aortic ROS overproduction. The hypotheses that inflammatory 
cytokines play a pivotal role, and that sildenafil is able to attenuate or abolish those 
endothelial dysfunctions, were also tested.
Materials and Methods
Animals
The experiments were conducted in adult (18-week-old) male apoE-/- mice that had a C57BL/6J 
genetic background, and in wild-type (WT) mice. The animals were bred and maintained in the animal care 
facility at the Laboratory of Translational Physiology of the Health Sciences Center of the Federal University 
of Espírito Santo, Brazil. The mice were housed in individual acclimatized plastic cages with temperature 
control (22-23°C) and humidity (60%) and were exposed to a 12/12-h light–dark cycle. All experimental 
procedures were performed in accordance with the guidelines for the care and handling of laboratory 
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animals as recommended by the National Institutes of Health (NIH), and the study protocols were approved 
by the Institutional Animal Care Committee (CEUA).
To accelerate the spontaneous hyperlipidemia and the progression of endothelial dysfunction and AT, 
the apoE-/- animals were fed a Western-type diet for 10 weeks, beginning at 8 weeks of age. After 7 weeks 
(15-week-old), the apoE-/- mice were divided into the following groups: a) apoE-/- mice treated with the 
PDE5 inhibitor, sildenafil (Viagra®, 40 mg/kg/day, for 3 weeks, by oral gavage), and b) apoE-/- mice treated 
with the vehicle. Wild-type  mice were used as negative controls.
Plasma lipids profile
Blood samples were obtained by puncturing the animals’ right ventricles, after euthanization with an 
overdose of sodium thiopental (Cristalia, Sao Paulo, Brazil, 200 mg/kg, i.p.). The blood was immediately 
transferred to a tube containing heparin and centrifuged at 956 g for 10 min. Plasma was separated 
immediately and kept at −20 °C until assayed. The levels of total plasma cholesterol, high density lipoproteins 
(HDL) and triglycerides were measured using commercial colorimetric assay kits (Bioclin, Belo Horizonte, 
Brazil). The levels of non-HDL were estimated by subtracting HDL from total serum cholesterol.
Vascular function
At the end of the treatment, animals were euthanized as previously described (see above) and 
the descending thoracic aorta was carefully excised by midline abdominal incision, and cleaned of fat 
and connective tissue, taking care to do not stretch the vessel excessively to ensure the integrity of the 
endothelium. Next, the aorta was then cut into small rings (~ 3 mm length) and placed in cold Krebs–
Henseleit buffer with the following composition (in mM): NaCl 115, KCl 4.7, CaCl2•2H2O, 2.5, MgSO4•7H2O 
1.2, KH2PO4 1.2, NaHCO3 25, EDTA 0.01 and glucose 11.1.
Aortic rings were then mounted on stainless steel triangles, suspended in vertical organ baths 
containing 5 mL Krebs solution, maintained at a resting tension of 0.5 g at 37°C, pH 7.4 and continuously 
gassed with a mixture of 95% O2 and 5% CO2. The rings were connected to force transducers to measure 
isometric tension using a computerized acquisition system (MP100, Biopac Systems Inc., Santa Barbara, 
USA).
After a 60-min equilibration period, aortic rings were exposed to KCl (125 mM) to assess their maximal 
tension. After washout (30 min), aortic rings pre-contracted with the α-agonist phenylephrine (PE, 10 
µM) were challenged with the vasodilator acetylcholine (10 μM). Relaxing responses greater than 60% 
indicated the presence of intact endothelial cells [18]. After washout with fresh buffer solution (30 min) and 
an equilibration period for 30 minutes, the contractile responsiveness of aortic rings was tested through 
cumulative concentrations of PE (from 100 pM to 30 mM).
To evaluate the relative contribution of endothelium-derived vasoactive factors to hypercontractile 
responsiveness, we initiated contractile response analyses. Thus, after another washout, the contractile 
responses of aortic rings to PE were repeated, after previous incubation for 20 min with one of the 
following agents: a) selective Cox-1 inhibitor (SC-560, 1 μM), b) selective Cox-2 inhibitor (NS-398, 1 μM) or 
c) thromboxane-prostanoid receptor (TP) antagonist (SQ 29548, 1 μM).
The curve-concentration responses were analyzed based on the calculation of the a) area under the 
curve (AUC) when testing the responsiveness to PE or endothelin 1, or the difference in the area under the 
curve (∆ AUC), when comparing concentration-response curves to PE before and after an inhibitor, expressed 
in arbitrary units (a.u.), b) the sensitivity of aortic rings to PE or endothelin 1, which was estimated using 
the pEC50 (−log EC50) and c) the efficacy  estimated using the maximum response (Rmax) to PE or endothelin 
1 in both conditions.
Contribution of oxidative stress to enhanced contractile vascular responsiveness
At the end of the treatment, the lucigenin-derived chemiluminescence assay was used to determine 
superoxide anion (•O2-) levels in the aorta. Isolated vascular ring segments (3 mm), obtained as described 
in the previous section were acutely incubated in saline phosphate buffer. Luminescence was quantified in a 
luminometer (Orion II luminometer, Berthold Detection Systems, Pforzheim, Germany) and the results are 
expressed as percentage of control group (arbitrary units).
Determination of cytokines in aortic tissue using cytometric bead array
The levels of inflammatory interleukin 6 (IL-6) chemokine (MCP-1) and tumor necrosis factor 
alpha (TNF-α) cytokines, and the anti-inflammatory IL-10 cytokine were measured in the aortic tissue by 
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flow cytometry using a cytometric bead array, according to the manufacturer’s instructions described in a 
mouse inflammation Kit, (CBA - BD Biosciences, San Diego, CA, USA). The BD CBA system uses the sensitivity 
of amplified fluorescence detection by flow cytometry to measure different soluble analytes in a particle-
based immunoassay in a single sample. Based on the manufacturer’s recommended procedure, a typical 
forward and side scatter gate was set to exclude aggregates; a total of 5, 000 events in the gate were analyzed 
using FACSCanto II and FACSDiva Software (BD). Samples were quantified by comparing them with standard 
curves of recombinant cytokines using FCAP Array software (BD). The results are expressed as pg/mL.
Statistical analysis
The values are expressed as means±SEM. The Gaussian distribution of the variables was previously 
analyzed using the D’Agostino-Pearson omnibus normality test. Fitting concentration-response curves were 
constructed and analyzed using nonlinear regression analysis. Statistical comparisons between the different 
groups were performed by one- or two-way analysis of variance (ANOVA), followed by Bonferroni’s post hoc 
test. Differences between means with a value of p<0.05 were considered statistically significant. Statistical 
software: Prism 7.0, GraphPad Software Inc.
Results
Plasma lipid profiles
The plasma lipid profiles of the three groups of animals are summarized in Table 1. 
ApoE-/- mice showed a significant increase in triglycerides (~3-fold, p<0.001), total plasma 
cholesterol (~14-fold, p<0.001) and non-HDL (~28-fold, p<0.001), and the treatment with 
sildenafil did not modify these differences in relation to the wild-type group. As expected, 
HDL was significantly reduced (~2- fold, p<0.001) in both the non-treated and the sildenafil-
treated apoE-/- groups, compared with wild-type mice.
Contractile response to α1-adrenoceptor stimulation
Fig. 1 summarizes the results of the evaluation of PE-induced contractions in aortic rings 
from the apoE-/- and wild-type groups. As shown in the line-graph, the apoE-/- group exhib-
ited a left- and upward-shift in the concentration-response curve to PE when compared with 
the wild-type animals (p<0.05), indicating an enhanced contractile responsiveness in those 
atherosclerotic animals. In contrast, the curve of apoE-/- mice treated with sildenafil was 
right- and downward-shifted, close to the concentration-response curve of wild-type mice. 
Accordingly, apoE-/- mice exhibited a significant increase in efficacy  (Rmax ~35%, p<0.01), 
sensitivity (~7%, p<0.01) and AUC (~44%, p<0.01) when compared with wild-type mice, 
and the treatment with sildenafil completely supressed these parameters (Rmax: 31%, sensi-
tivity: 7% and AUC: 39%, p<0.05 vs apoE-/- mice; p>0.05 vs. wild-type mice) as demonstrated 
in the table at the bottom of  Fig. 1.
Contribution of the cyclooxygenase-2 pathway to enhanced contractility
Following the demonstration of an exacerbated vasoconstriction to PE in apoE-/- mice, 
Table 1. Serum lipid profiles of sildenafil-
treated apoE-/- mice compared with non-
treated apoE-/- mice and wild-type control 
mice. Values are means ± SEM. *p<0.05 vs. WT 
(one-way ANOVA)
we focused our analysis on the contribution of the 
prostanoid molecular pathway in this abnormal 
response. The average data of concentration–
response curves to PE and the respective 
parameters are shown in the line-graphs and in the 
bottom table in Fig. 2, comparing the PE-induced 
values before and after the specific Cox-2 blockade 
with NS-398 in the three groups of animals. No 
significant differences were observed in the 
concentration-response curves (line-graphs) or 
in the parameters of the curves (bottom table) 
obtained before and after incubation of the aortic 
rings with NS-398 in the wild-type group. Similarly, 
pre-incubation of aortic rings with the specific of 
Cox-2 inhibitor caused only a trend towards an 
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upward shift (p>0.05) in the curves, indicating a worsening of contractile hyperresponsiveness 
to PE in the apoE-/- group. In the group apoE-/- mice, in which hypercontractility to PE had 
been normalized by the treatment with sildenafil, pre-incubation with the NS-398 inhibitor 
did not cause additional significant changes in the concentration-response curves when 
compared with the data obtained without the Cox-2 blockade. These data suggest that the 
Cox-2-derived pathway does not contribute to the vascular hyperresponsiveness exhibited 
by apoE-/- mice.
Contribution of the cyclooxygenase-1 pathway to hypercontractility responsiveness
Next, we evaluated the relative contribution of Cox-1 to this process in a different group 
of animals, using SC-560, a specific inhibitor of this pathway. As indicated in the upper panel 
graphs and in the respective parameters in the bottom table (Fig. 3), pre-incubation of aortic 
rings with the Cox-1 inhibitor did not modify the curve parameters in the wild-type group. 
However, this blockade caused a right- and downward shift in the concentration-response 
curve to PE in aortic rings from apoE-/-mice (line-graph of Fig. 3). Accordingly, the maximum 
response (Rmax) was significantly reduced (39%, p<0.05) and consequently the difference in 
AUC was significantly augmented (2.7-fold, p<0.05) when compared with the wild-type group. 
In contrast, pre-incubation of aortic rings with the Cox-1 inhibitor did not cause significant 
effects on the parameters of the concentration-response curves of apoE-/- mice treated with 
sildenafil, in which treatment with sildenafil had already normalized the concentration-
response curve to PE.
Contribution of TXA2 to enhanced contractile responsiveness
Next, we evaluated the contribution of TXA2 to hyperresponsiveness in the 
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Figure 2.  
Fig. 1. The effect of chronic treat-
ment with sildenafil on phenyl-
ephrine-induced contraction in 
aortic rings from apoE-/- mice. 
Rmax (maximum PE-induced con-
tractions), AUC (area under the 
curve) and pEC50 (sensitivity). Val-
ues are means±SEM. *p<0.05 vs. 
Wild-Type mice; #p<0.05 vs. apoE-/- 
mice. Two-way ANOVA for repeat-
ed measurements (pEC50 and Rmax), 
and one-way ANOVA (∆AUC).
Fig. 2. The contribution of the prostanoids derived from Cox-2 to PE-
induced vasoconstriction in aortic rings from apoE-/- mice compared to 
nontreated apoE-/- and wild-type mice. NS-398 is a selective Cox-2 in-
hibitor. The table shows the maximum vasoconstrictor response (Rmax) 
to KCl, sensitivity (pEC50) to PE and the difference between areas un-
der the curve before and after the Cox-2 inhibitor in the same group. 
The values are means ± SEM. *p<0.05 vs. respective wild-type column; 
#p<0.05 vs non-treated apoE-/- group . Two-way ANOVA for repeated 
measurements (pEC50 and Rmax), and one-way ANOVA (∆AUC).
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concentration–response curves to PE under the effect of the TP antagonist SQ-29.548 (1 μM) 
in the three groups of animals. As indicated in the upper panel graphs and in the respective 
parameters in the bottom table, pre-incubation of aortic rings with the TP antagonist did 
not modify the sensitivity in the previous response to PE in the three groups of animals 
(p>0.05). However, in terms of Rmax and AUC, a reduction in the concentration-response 
curve to PE was observed. For instance, when we compared the AUC in the presence and 
absence of blockade as demonstrated in Fig. 4, a minor reduction was noted in the wild-type 
group (-17% p<0.05), but this reduction was significantly greater in the apoE-/- mice (-26 % 
p<0.05). Interestingly, treatment with sildenafil normalized this parameter (-18 % p<0.05). 
On the other hand, the Rmax to PE under the TP blockade was significantly decreased in 
apoE-/- mice (- 23%, p <0.05), but it was not significant either in wild-type (-14% p>0.05) or 
Fig. 3. The contribution of the 
prostanoids derived from Cox-
1 to the PE-induced vasocon-
striction in aortic rings from 
apoE-/- mice compared to non-
treated apoE-/- and wild-type mice 
using the selective Cox-1 inhibitor 
SC-560. The table shows the max-
imum vasoconstrictor response 
(Rmax) to KCl, sensitivity (pEC50) 
to PE and the difference between 
areas under the curve (∆AUC) be-
fore and after the Cox-1 inhibitor 
in the same group. The values are 
means±SEM. *p<0.05 vs. respec-
tive wild-type column; &p<0.05 
vs control group; #p<0.05 vs non-
treated apoE-/- group . Two-way 
ANOVA for repeated measure-
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Figure 3.  
Fig. 4. The contribution of throm-
boxane A2 (TXA2) to the PE-in-
duced vasoconstriction in aortic 
rings from apoE-/-mice compared 
to nontreated apoE-/- and wild-
type mice. SQ-29548 is a selective 
thromboxane receptor antagonist. 
The table shows the maximum 
vasoconstrictor response (Rmax) to 
KCl, sensitivity (pEC50) to PE and 
the difference between areas un-
der the curve (∆AUC) before and 
after the TP antagonist in the same 
group. The values are means±SEM. 
*p<0.05 vs. respective wild-type 
column; &p<0.05 vs control group; 
#p<0.05 vs non-treated apoE-/- 
group. Two-way ANOVA for re-
peated measurements (pEC50 and 
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Figure 6.  
 




in apoE-/- mice treated with sildenafil (-8%, 
p>0.05).
Contractile vascular responsiveness to 
endothelin-1
Having established that both Cox-1 
and the TXA2 pathways have an important 
relative contribution to the vascular 
hypercontractility to PE in apoE-/- mice, 
we decided to evaluate the role of the 
endogenous vasoconstrictor endothelin-1. 
Fig. 5 summarizes the results of the evaluation 
of endothelin-induced contractions in aortic 
rings from all groups. As expected, aortic rings 
of apoE-/- animals exhibited an enhanced 
contractile response to endothelin-1 when 
compared with wild-type animals, as 
indicated by the three main concentration-
response curve parameters (bottom of Fig. 
5). The data showed a significant increase in 
efficacy (~68%), sensitivity (~7%) and AUC 
(~2-fold) in apoE-/- mice when compared with 
wild-type mice (p<0.05). Looking at figure 5, 
we see that among the three parameters of 
the curve response to endothelin-1, the one 
most affected by sildenafil treatment was 
Rmax (-32%p<0.05), with small changes in all 
other parameters.
Contribution of oxidative stress to en-
hanced contractile vascular responsive-
ness
We also evaluated the oxidative stress 
by measuring •O2-, the most important ROS. 
Fig. 6 shows the production of •O2- generated 
in the three groups of animals, which was 
significantly augmented in aortas from 
apoE-/- (2.6-fold, p<0.05) when compared 
with wild-type control animals. In the group 
of apoE-/- treated with sildenafil, the levels of 
•O2- were attenuated 1.7-fold (p<0.05).
Aortic inflammatory cytokines
In a separated group of animals, we 
evaluated the levels of proinflammatory IL-
6, MCP-1 and TNF-α cytokines, and the anti-
inflammatory IL-10 cytokine in aortic tissue. 
As expected and as shown in Fig. 7, aortas 
from apoE-/- mice showed augmented levels 
of the proinflammatory cytokine IL-6 (3-
fold, p<0.05) when compared with wild-type 
Fig. 5. Dose-response curves showing the aortic 
responsiveness to the vasoconstrictor endothelin-1 
in apoE-/- mice and the beneficial effect of sildenafil. 
The table shows the area under the curve (AUC), 
the maximum vasoconstrictor response (Rmax) and 
the sensitivity (pEC50) in each group. The values 
are means±SEM. *p<0.05 vs. wild-type and #p<0.05 
vs. non-treated apoE-/- group. Two-way ANOVA for 
repeated measurements (pEC50 and Rmax), and one-
way ANOVA (∆AUC).
Fig. 6. The effect of sildenafil treatment on super-
oxide anion levels in aortic tissue in apoE-/- mice. 
The values are means±SEM (n= 6 to 8 animals per 
group. *p<0.05 vs. Wild-Type mice and #p<0.05 vs. 
non-treated apoE-/- group (1-way ANOVA). Two-way 
ANOVA for repeated measurements (pEC50 and Rmax), 
and one-way ANOVA (∆AUC).
mice, and this difference was significantly attenuated by chronic treatment with sildenafil 
(1.6-fold, p<0.05). Although no significant changes in the anti-inflammatory IL-10 were 
observed when compared with the wild-type group, the apoE-/- mice exhibited a significant 
reduction in the IL-10/IL-6 ratio (3.3-fold, p<0.05) when compared with wild-type mice. The 
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aortic chemokine TNF-α was also significantly augmented in apoE-/- mice (1.2-fold, p<0.05), 
and the treatment with sildenafil did not have significant effects. The level of tissue cytokine 
MCP-1 was also significantly augmented (2-fold, p<0.05) and this difference was attenuated 
with chronic treatment with sildenafil (1.6-fold, p<0.05).
Discussion
This study was designed to elucidate the mechanisms involved in the vascular hyper-
contractility of aortic rings from apoE-/- mice and to test the beneficial effects of the PDE 5 
inhibitor sildenafil on this abnormal response.  Our data show a hyperactivation of COX-1/
TXA2 pathway and an exacerbated contractile response to ET-1 beyond the increased levels 
of proinflammatory cytokines and •O2-. Interesting that the exacerbation of these four differ-
ent but complementary pathways was successfully attenuated by sildenafil, reinforcing the 
vascular protective effects exhibited by this PDE5 inhibitor.
In the present study, we observed a hypercontractility in aortic rings from apoE-/-, which 
is in agreement with previous data from our laboratory [18] and with other studies that 
have observed enhanced vasoconstrictions even in apoE+/-, a model of mild dyslipidemia 
[28]. Data from previous studies suggest that the exacerbated vascular contractile response 
to α1-adrenoceptor agonists, which was observed in the apoE-/- murine model, could be 
mediated by altered vascular responsiveness to endogenous vasoconstrictors and an 
imbalance of the vasodilatory/vasoconstriction prostanoid pathways [18, 20]. It has also 
been suggested that this hypercontractile response to phenylephrine (Rmax) is due to higher 
levels of cytosolic Ca2+ concentration ([Ca2+]c) in the smooth muscle cells of apoE-/- mice [29]. 
Accordingly, it has been established that Cox-derived pro-inflammatory prostanoids play 
a pivotal role in the generation of endothelial dysfunction and AT [26, 30-32]. Cox-1 and 
Cox-2 convert arachidonic acid to final vasoactive prostanoids, including balanced actions 
of PGI2 and TXA2 to maintain the regulation of vascular function [33]. In general, Cox-1 is 
constitutively expressed in most tissues, whereas Cox-2 is an inducible isoform by various 
physiological stimuli such as inflammation and shear stress [34-38]. However, few studies 
have been conducted to evaluate the role of these endothelial enzymes in the apoE-/- murine 
model. Therefore, the novelty of the present study includes the elucidation of the relative 
role of Cox-1 and Cox-2 mediating the hypercontractility induced by phenylephrine, and the 
pleiotropic effects of the PDE-5 inhibitor sildenafil on the Cox-1 and Cox-2 pathways.
The activation of Cox, the diffusion of endothelium-dependent contracting factors 
towards the smooth muscle cells, and the subsequent stimulation of their TP are important 
contributors to endothelial dysfunction [39]. In apoE-/- mice, in which elevated production 
of TXA2 [34] has been observed, interruption of TXA2 signaling by deletion of its receptor 
Fig. 7. The effect 
of sildenafil treat-
ment on the proin-
flammatory inter-
leukin (IL-6), the 
anti-inflammatory 
IL-10 and the IL-





(MCP-1) and tumor 
necrosis factor al-
pha (TNF-α) are 
also shown. Values are means±SEM (n= 6 to 8 animals per group. *p<0.05 vs. Wild-type mice and #p<0.05 vs. 
non-treated apoE-/- group (One-way ANOVA).
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(TP) limits atherogenesis [40]. By using the specific inhibitors SC-560 for Cox-1 and NS-398 
inhibitor for Cox-2 (Fig. 3), we observed that Cox-1 prevails over Cox-2 in the mediation 
of the endothelium-dependent vasoconstrictor response to PE apoE-/- mice. This is in 
agreement with the finding that aortic endothelial cells preferentially express Cox-1 versus 
Cox-2 [31, 41], and that as Cox-1 expression is increased, the major source of vasoconstrictor 
prostanoids is converted into the endothelial cells, which diffuse to contract the underlying 
vascular smooth muscle in arteries of mouse models of cardiovascular diseases [31, 42]. 
Importantly, chronic treatment with sildenafil normalized the vascular hypercontractility 
(Rmax) in this model of AT. Interestingly, pre-incubation of the aortic rings with the TXA2 
inhibitor SQ-29548 (data in Fig. 4) reduced hypercontractility to PE to a similar extent to 
that observed when the aortic rings were pre-incubated with a specific Cox-1 inhibitor. 
Therefore, using different protocols, our data indicate that Cox-1, but not Cox-2 is an 
important contributor to the endothelium-dependent hypercontractility observed in the 
apoE-/- mouse model of AT, which is in agreement with other studies [40]. The present data 
is also corroborated by other studies that show that activation of TP is of high relevance for 
vasoconstriction [26, 43-46], and that the pharmacological antagonism of TXA2 can delay the 
progression of AT [47, 48]. This could be explained by the fact that the activation of TP lead 
to the increase in [Ca+2]c, a critical step for vasoconstriction and the atherosclerotic process 
[18, 49, 50]. In addition, other studies have shown that TXA2 up-regulates NADPH oxidase 
[42, 51, 52], increasing the levels of superoxide anion, which reacts with NO, compromising 
its bioavailability and its vasodilator activity. This hypothesis is supported by the present 
data showing a significant increase (more than 2-fold) of superoxide anions in aortic tissue 
of apoE-/- mice (Fig. 6). The novelty of the present study is the demonstration that sildenafil 
treatment was able to correct the Cox-1/TXA2 pathway disturbance. However, one cannot 
rule out the participation of other endothelium-derived vasocontractile agents.
We also considered a possible contribution of ET-1 to the hyperreactivity in this 
atherosclerotic model. This peptide is a potent vasoconstrictor that is continuously secreted 
by vascular endothelial cells and acts on the underlying smooth muscle cells through ETA 
receptors that increase [Ca+2]c, [53-56], potentiating the TXA2 pathway. It has been associated 
with many forms of cardiovascular disease [57, 58]. Based on this concept, and considering 
the evidence that conductance vessels from atherosclerotic apoE-/- mice exhibit an 
overproduction of ET-1 and ETA hypersensitivity [58-60], we evaluated the responsiveness 
in aortic rings from apoE-/- to ET-1. Our data show an exacerbated vascular contractile 
response to ET-1 in apoE-/- mice, which could also contribute (via NADPH oxidase) to the 
overproduction of •O2- and to the increased degree of endothelial dysfunction [53, 61] that 
we observed in the present study. Moreover, it has been shown that activation of Cox is a 
source of •O2-because of its ability to co-oxidize substances such as NADPH [36], which 
corroborates the present study. Therefore, our cumulative findings show an overproduction 
of vascular ROS (Fig. 6), an exacerbated contraction force of aortic rings to TXA2 (Fig. 4) and 
enhanced response to ET-1 (Fig. 5) in apoE-/- mice. This led us to determine whether sildenafil 
could minimize these synergic mechanisms in the progression of endothelial dysfunction.
Recent data have demonstrated that •O2- may upregulate PDE4 and PDE5, which 
rapidly inactivates the second messengers involved in vasodilation such as cyclic adenosine 
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) [15, 18, 62]. 
Additionally, superoxide anions appear to stimulate the production of TXA2 and 8-isoprostane, 
an equipotent agonist of TP [52, 62] and ET-1 [63, 64]. Thus, pharmacological strategies such 
as pleiotropic drugs to interrupt this vicious cycle cascade seem to be relevant against AT. 
In fact, in the present study we observed that treatment of apoE-/- animals with this PDE5 
inhibitor reduced the vascular hyperactivity probably by decreasing the TP/ET-1/NADPH 
oxidase activity. Previous reports from our laboratory and other studies have revealed that 
sildenafil, besides having vasodilatory effect (by preserving cGMP signaling and consequently 
reducing [Ca+2]c) presents additional anti-atherosclerotic effects, such as: exhibiting indirect 
antioxidative and antigenotoxic activity [15, 21, 23], increasing the number and function 
of endothelial progenitor cells [21], and reducing significantly lipid deposition in the 
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conductance arteries, even under dyslipidemia [15, 18]. Confirming our previous observations, 
the new finding in this issue is that treatment with sildenafil shifted the exacerbated contractile 
response to TP and ET-1 close to that exhibited by normal wild-type animals. These responses 
can be explained by three main factors: 1) normalization of [Ca+2]c in smooth vascular muscle 
cells by increasing cGMP, correcting this abnormal pathway; 2) reduction of levels •O2-, restoring 
the bioavailability of NO and lastly (and most surprisingly) the reduction of proinflammatory 
IL-6, TNF-α and MCP-1 (important stimulators of ROS) [8, 19, 65-67]. In addition to the data 
relating to changes in vascular inflammatory cytokines, we are demonstrating, for the first time, 
evidence of an anti-inflammatory effect of sildenafil in atherosclerotic apoE-/- mice (Fig. 7).
AT is characterized by chronic inflammation and enrichment of inflammatory cells in the 
vessel wall [39]. The crucial role of pro-inflammatory cytokines (e.g., MCP-1, TNF-α and IL-6) 
in the initiation and progression of AT is well documented [8, 28, 65-67]. However, there are 
many challenges when studying the immune system in mice aortic tissues, due to the size and 
the number of cells obtained from the aorta. As a solution, techniques such as polymerase chain 
reaction and immunohistochemistry can be useful, although they also have some limitations, such 
as poor correlation between mRNA and protein and semi-quantitative data, respectively [68-70]. 
In this study, we demonstrated, for the first time, an increase of IL-6, TNF-α and MCP-1 proteins 
in aortas of apoE-/- mice using the cytometry assay (Fig. 7). The observation that the ratio anti-
inflammatory/proinflammatory cytokines was markedly reduced in the atherosclerotic animals 
and significantly attenuated by the treatment with sildenafil was also important. Previous 
studies have shown that MCP-1 plays an important role in the recruitment and trans-endothelial 
migration of monocytes in early atherogenesis [1, 71, 72]. At the same time, IL-6 is an important 
biomolecule that increases the oxidative stress, promotes fatty streaks and induces leukocytes 
recruitment into the sub-endothelial space [65, 73]. This led us to propose that  the reduction 
of pro-inflammatory mediators by sildenafil might be justified by an increase in cGMP. This 
possibility is supported by previous findings in other experimental models demonstrating that 
intracellular cGMP diminishes cytokine production and oxidative stress, thereby modulating the 
inflammatory response [74-76].Therefore, it seems reasonable to consider that the correction 
of the enhanced contractile responsiveness promoted by sildenafil in aortic rings from apoE 
-/- mice could act, at least in part, via its antioxidant properties and indirect interaction with 
pro-inflammatory mediators, highlighting the benefits of the pleiotropic effects of sildenafil, as 
observed in other experimental models [4, 22].
Conclusion
A schematic summary of the present data is shown in Fig. 8. Our data show that the 
enhanced vasoconstriction of aortic rings from atherosclerotic mice is mediated by Cox-
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tion in the 
apoE-/- mouse 
model of AT 
and the ben-
eficial effects of 
sildenafil based on the present data. AA: arachidonic acid, α1: α1-adrenoceptor, Cox: Cyclooxygenase, ET-1: En-
dothelin-1, ETA: Endothelin-A receptor, IL-6: Interleukin-6, MCP-1: Monocyte chemoattractant protein-1, oxLDL: 
oxidized low-density lipoprotein, PE: Phenylephrine, PGI2: Prostacyclin, ROS: Reactive oxygen species, S: possible 
actions of sildenafil, TNF-α: tumor necrosis factor alpha cytokine, TP: thromboxane-prostanoid receptor antago-
nist, TXA2: thromboxane A2.
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independently of the preserved hypercholesterolemia. Additionally, the antioxidative and 
immunomodulatory properties of sildenafil (i.e., reduction of •O2-, IL-6 and MCP-1 and an 
increase in IL-10/IL-6 ratio) might explain, at least in part, the vascular protective effects 
exhibited by this PDE5 inhibitor. The present data provide new insights into the mechanisms 
involved in endothelium-dependent hypercontractility in this murine model of AT, and shows 
that the beneficial effects of chronic treatment with sildenafil on endothelial dysfunction in 
this model open new perspectives for treatment of other endothelium-related cardiovascular 
diseases.
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